Highlights
- •There was a longitudinal association between changes in brain volume (SIENA) and SDMT but not with PASAT.
- •One percent decrease in brain volume was associated with 1.5 letters decrease on low contrast visual acuity
- •Baseline nBPV, nGMV and nNAWMV predicted subsequent changes in disability as measured by MSFC but not EDSS.
Abstract
Objectives
To study the association between changes in brain magnetic resonance imaging (MRI)
and clinical outcomes in early MS.
Methods
MS patients within 12 months of onset were enrolled and followed up to 3 years. Clinical
measures included Symbol Digit Modalities Test (SDMT), MS Functional Composite (MSFC)
and low contrast letter acuity (LCLA). MRI outcomes included brain volume changes
measured by SIENA and SIENAX normalized measurements [brain parenchymal volume (BPV),
normal-appearing white and gray matter volume (NAWMV and GMV) and T2 lesion volume
(T2LV)]. Mixed model regression measured time trends and associations between imaging
and clinical outcome.
Results
Forty-three patients were enrolled within 7.5±4.9 months of onset. Baseline T2 lesion
volume predicted subsequent changes in Paced Auditory Serial Addition Test (PASAT)
(p=0.004), whereas baseline measures of atrophy including BPV, GMV, and NAWMV predicted
longitudinal changes in MSFC (p=0.016, p=0.040, p=0.021, respectively) and Timed-25 Foot Walk (p<0.05). Each 1% decrease in SIENA was associated with 1.14 point decrease in SDMT
score (p=0.03). Each 1% decrease in brain volume SIENA was associated with almost 1.5 letters
decrease on LCLA (p=0.02).
Conclusion
Measures of lesion volume and overall brain volume were associated with different
long-term clinical outcome measures in early MS.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates.J Neurol. 2007; 254: 1588-1594
- Contrast letter acuity as a visual component for the multiple sclerosis functional composite.Neurology. 2003; 61: 1367-1373
- New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis.Mult Scler. 2000; 6: 163-171
- Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity.Neurology. 2010; 74: S16-S23
- Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.Nat Rev Neurol. 2009; 5: 256-266
- Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).J Int Neuropsychol Soc. 2006; 12: 549-558
- Minimal neuropsychological assessment of MS patients: a consensus approach.Clin Neuropsychol. 2002; 16: 381-397
- Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.Am J Neuroradiol. 2012; 33: 1573-1578
- Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.Mult Scler. 2008; 14: 1242-1249
- Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans.Psychiatry Res. 2011; 193: 182-190
- Development of a multiple sclerosis functional composite as a clinical trial outcome measure.Brain: J Neurol. 1999; 122: 871-882
- Psychometrics and normative data for the multiple sclerosis functional composite: replacing the PASAT with the symbol digit modalities test.Mult Scler. 2010; 16: 228-237
- Cognitive impairment in multiple sclerosis.in: Cook S.D. Handbook of multiple sclerosis. Marcel Dekker, New York2001: 233-255
- Gray matter atrophy in multiple sclerosis: a longitudinal study.Ann Neurol. 2008; 64: 255-265
- Cognitive deterioration in patients with early multiple sclerosis: a 5-year study.J Neurol Neurosurg Psychiatry. 2012; 83: 38-43
- Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.Ther Adv Neurol Disord. 2010; 3: 229-239
- Paced auditory serial-addition task: a measure of recovery from concussion.Percept Mot Skills. 1977; 44: 367-373
- Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.Neurology. 2004; 63: 335-339
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.Mult Scler. 2013;
- Neuroprotection in multiple sclerosis: a therapeutic approach.CNS Drugs. 2013; 27: 799-815
- Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.Ann Neurol. 2001; 50: 121-127
- Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline.Clin Neuropsychol. 2010; 24: 1131-1145
- Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures.Neurology. 2009; 72: 1760-1765
- One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis.Am J Ophthalmol. 2011; 152: 133-140
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”.Ann Neurol. 2005; 58: 840-846
- Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.Neurology. 1991; 41: 685-691
- Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.J Neurol Sci. 2009; 282: 106-111
- The measurement of ambulatory impairment in multiple sclerosis.Neurology. 1997; 49: 1419-1424
- Brain atrophy in multiple sclerosis: what we know and would like to know.Mult Scler. 2006; 12: 679-687
- Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.NeuroImage. 2002; 17: 479-489
- A comprehensive review of the Paced Auditory Serial Addition Test (PASAT).Arch Clin Neuropsychol: Off J Natl Acad Neuropsychol. 2006; 21: 53-76
- A phase II trial of neuroprotection with riluzole in early relapsing-remitting MS.Mult Scler. 2013; 19: 560
- Relation of vision to global and regional brain MRI in multiple sclerosis.Neurology. 2007; 69: 2128-2135
- Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm.IEEE Trans Med Imaging. 2001; 20: 45-57
Article info
Publication history
Published online: July 23, 2014
Accepted:
July 15,
2014
Received in revised form:
July 12,
2014
Received:
May 29,
2014
Identification
Copyright
© 2014 Published by Elsevier Inc.
